Work

Initial testing (stage 1) of SGI‐1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program

Year: 2011

Type: article

Abstract: The PIM kinase inhibitor, SGI-1776, was tested against the PPTP in vitro (1.0 nM-10 µM) and in vivo panels (148 mg/kg daily × 5 days for 3 weeks). SGI-1776 exhibited cytotoxic activity in vitro with a median relative IC(50) of 3.1 µM. SGI-1776 induced significant differences in EFS distribution in vivo in 9 of 31 solid tumor xenografts and in 1 of 8 of the evaluable ALL xenografts. SGI-1776 induced tumor growth inhibition meeting criteria for intermediate EFS T/C activity in 1 of 39 evaluable models. In contrast, SGI-1776 induced complete responses of subcutaneous MV4;11 (B myeloid leukemia).

Source: Pediatric Blood & Cancer

DOI: 10.1002/pbc.23364

Authors: Vandana Batra, John M. Maris, Min H. Kang, C. Patrick Reynolds, Peter J. Houghton, Denise Alexander, E. Anders Kolb, Richard Gorlick, Stephen T. Keir, Hernan Carol, Richard Lock, Catherine A. Billups, Malcolm A. Smith

Institutions: Children's Hospital of Philadelphia, University of Pennsylvania, Texas Tech University, Texas Tech University Health Sciences Center, Nationwide Children's Hospital, Alfred I. duPont Hospital for Children, Children's Hospital at Montefiore, Duke Medical Center, Children's Cancer Institute Australia, St. Jude Children's Research Hospital, National Cancer Institute

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Cancer Australia, University of New South Wales, National Institutes of Health, National Cancer Institute

Awards: G1215897271, Pediatric Preclinical Testing Program, G1628177865, G3738888336, G5277985768, G609259107, SPORE in Brain Cancer, Cancer Center Support Grant (CCSG)

OpenAlex ID: W1978073487

FWCI: 3.138

Cites: 20

Cited by: 24

Related to: 10